Jiuzhitang announced that net profit for the first half of 2026 is expected to be 241 million yuan to 264 million yuan, an increase of 67.63%-83.63% over the previous year. Harbin Jixianglong Biotechnology Co., Ltd. was included in the scope of the Company's consolidated statement in November 2025. During the reporting period, the company's production and operation conditions were good, which led to a year-on-year increase in the company's net profit. The optimization and adjustment of the structure and marketing system transformation of the company's original main business segment have gradually shown results. Sales of most products have increased. At the same time, through various measures such as deepening lean management and strengthening cost control, operational efficiency and management levels have been improved, and overall business performance has grown.

Jiuzhitang announced that net profit for the first half of 2026 is expected to be 241 million yuan to 264 million yuan, an increase of 67.63%-83.63% over the previous year. Harbin Jixianglong Biotechnology Co., Ltd. was included in the scope of the Company's consolidated statement in November 2025. During the reporting period, the company's production and operation conditions were good, which led to a year-on-year increase in the company's net profit. The optimization and adjustment of the structure and marketing system transformation of the company's original main business segment have gradually shown results. Sales of most products have increased. At the same time, through various measures such as deepening lean management and strengthening cost control, operational efficiency and management levels have been improved, and overall business performance has grown.